Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2016 07:00 ET | Source: ObsEva SA

ObsEva Announces Results of the IMPLANT Phase 2 Trial of OBE001 (nolasiban) for the Improvement of Pregnancy and Live Birth Rates Following IVF/ICSI

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Trial shows meaningful increase in...
October 17, 2016 07:00 ET | Source: ObsEva SA

ObsEva Announces Plans to Conduct Initial Public Offering in the United States

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} GENEVA, SWITZERLAND, 17 October, 2016 -...
October 12, 2016 07:00 ET | Source: ObsEva SA

ObsEva Randomizes First Patient in Phase 2b EDELWEISS Study of OBE2109 for the Treatment of Endometriosis

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - Clinical trial to assess safety and...
August 10, 2016 07:00 ET | Source: ObsEva SA

ObsEva to Present at 2016 Wedbush Pacgrow Healthcare Conference

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} PRESS RELEASE ObsEva to Present at...
July 28, 2016 07:00 ET | Source: ObsEva SA

ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2alpha Antagonist, for the Treatment of Preterm Labor

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} PRESS RELEASE ObsEva Initiates Phase...
July 06, 2016 07:00 ET | Source: ObsEva SA

ObsEva Receives Clearance from US FDA to Initiate Phase 2b Study EDELWEISS with OBE2109, a Potentially Best-in-Class Oral GnRH Antagonist, for the Treatment of Endometriosis

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} PRESS RELEASE ObsEva Receives Clearance...
April 05, 2016 08:00 ET | Source: ObsEva SA

ObsEva to Webcast Presentation at 15th Annual Needham Healthcare Conference

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 05 April, 2016 -...
March 24, 2016 08:08 ET | Source: ObsEva SA

ObsEva Strengthens Board with Appointment of Biotechnology Veteran Dr. Frank Verwiel

GENEVA, March 24, 2016 (GLOBE NEWSWIRE) -- ObsEva, a Swiss biopharmaceutical company innovating women's reproductive health and pregnancy therapeutics, today announced the appointment of Frank...
March 24, 2016 08:00 ET | Source: ObsEva SA

ObsEva Strengthens Board with Appointment of Biotechnology Veteran Dr. Frank Verwiel

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 24 March 2016 - ObsEva, a...
November 23, 2015 05:00 ET | Source: ObsEva SA

ObsEva Closes CHF 60 (USD 60) Million in Series B Financing

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 23 November 2015 -...